Amarin Corp Plc (AMRN)

[HinduKush]

Here we are in November 2020. It is shocking isn't it that a medicine like Vascepa proven by peer reviewed publication in January 2019 is still unheralded and ignored largely by mainline CV outcomes guidelines by the pre-eminent CV academic societies like AHA and ACC, even when as prominent a physician as Deepak Bhatt from the Haravrd health system is shouting its benefits till he is hoarse, and the evidence for its spectacular medical benefits keep piling up every week like some unread unwanted daily newspaper...the fish oil sneer is all too prevalent unfortunately in even physicians minds...
Consider this:
Number Needed to Treat ( NNT to save one adverse CV outcome):
NNT ACE inhibitors 128
NNT post MI for Beta Blockers is 42
NNT for antiplateleet agents eg clopidogrel 153
NNT for statins in secondary prevention 83 ( we all know how much third party payors HMO's and doctors love statins) and 39 for preventing MI
NNT for Vascepa in primary/secondary prevention is 21 (primary endpt) and 28 (secondary endpt)
If Vascepa had this sort of NNT but for improving outcomes in HIV do you think the politicians and government woudln't be pushing it forcefully and daily. As it is, apparaently, just dying from CVcauses eg MI CHF or needing costly debilitating CABG or PTCA/stenting is just not sexy enough for action, apparently...
HK